News

Nurix Therapeutics, Inc.: Nurix Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update
NX-5948 assigned the nonproprietary name "bexobrutideg"U.S. FDA Orphan Drug Designation granted to bexobrutideg for the treatment of Waldenström macroglobulinemiaAchieved $7M in milestones and a $15M ...
Nurix Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update
NX-5948 assigned the nonproprietary name “bexobrutideg”U.S. FDA Orphan Drug Designation granted to bexobrutideg for the treatment of Waldenström ...
Nurix Therapeutics reports Q1 EPS (67c), consensus (76c)
Reports Q1 revenue $18.45M, consensus $13.03M. “Nurix had a strong first quarter marked by important collaboration and regulatory achievements ...
NRIX Stock Up as SNY In-Licenses Rights to Autoimmune Diseases Program
Nurix stock gains as SNY expands its partnership, licensing a research program targeting a previously untreatable transcription factor for autoimmune diseases.
The Pharma Letter6d
Nurix expands licensing deal with Sanofi
US clinical-stage biotech Nurix Therapeutics (Nasdaq: NRIX) announced that Sanofi (Euronext: SAN) has exclusively licensed an ...